

E. Claude<sup>1</sup>, M. Snel<sup>1</sup>, P. Lee<sup>2</sup>, W. Chen<sup>2</sup>, J. Gebler<sup>2</sup>, T. McKenna<sup>1</sup>, J. Langridge<sup>1</sup>

<sup>1</sup>Waters Corporation, Manchester, UK

<sup>2</sup>Waters Corporation, Milford, MA, USA

### Overview

- A quick and easy N-terminal peptide modification reaction is described.
- This reaction, coupled with analysis by MALDI mass spectrometry provides improved protein sequence coverage, through the enhanced detection of small peptides.
- Derivatized peptides yield easily interpretable MS/MS spectra, with N-terminal fragments observed.
- The fragmentation mechanism of these modified peptides is discussed.
- Improvements in dynamic range and sequence coverage achievable by LC separation prior to MALDI MS or MS/MS analysis is discussed.

### Introduction

Peptide mass fingerprinting (PMF) by MALDI Tof mass spectrometry is a rapid and sensitive method for the identification of proteins from organisms with well-characterized genomes. PMF compares

experimentally observed peptide masses, obtained from the MALDI MS of enzymatically digested proteins, with theoretical peptide masses, obtained from the *in silico* digestion of proteins contained within protein sequence databases. This is a highly specific, sensitive technique for identifying proteins from a known proteome. However, the PMF approach will fail when a protein is not represented in the protein sequence database (e.g. if the genome has not been sequenced). In addition, problems occur due to non-specific enzyme activity, if some of the peptides are modified or too few tryptic peptides are observed to give an unambiguous answer. In these cases, further analysis and added specificity is gained by performing MS/MS on some of the peptide molecular ions and searching this information against a sequence database. If this fails to give an unambiguous answer then homology-based searching of the amino acid sequence information may allow identification of the parent protein.



Waters® Micromass® Q-ToF Ultima™ MALDI Mass Spectrometer.

With a hybrid quadrupole orthogonal acceleration time-of-flight (Q-ToF) mass spectrometer, equipped with a MALDI source, high quality MS/MS spectra can quickly be generated from MALDI phase samples. A feature of the oa-ToF mass analyzer is the high mass accuracy that is routinely achieved—typically better than 10 ppm RMS when using a single-point lockmass. Despite the quality of the MS/MS data obtained from this geometry of instrument, the MS/MS spectra generated from singly charged peptides, produced by the MALDI ionization process, exhibit a wide variety of fragment ions. The types of fragment ions produced are very sequence dependent. This can make interpretation of MALDI MS/MS data difficult due to their complexity.

A way of simplifying the spectrum and improving the fragmentation efficiency is to drive the fragmentation process by introducing a fixed charge at a specific location on the peptide.

This application note describes the use of an N-terminal derivatization strategy, using the N-Tris (2,4,6-trimethoxyphenyl) phosphonium-acetic acid N-hydroxysuccinimide ester (TMPP-acOSu) to improve MALDI MS/MS fragmentation patterns. Coupling of this peptide derivatization protocol with nanoscale HPLC separation and deposition onto a MALDI target is presented.

One advantage of this derivatization reagent is, that it increases the peptide masses by 572.182 Da. This mass increase can bring small peptides into the m/z range 800–3500, the typical range used in PMF analysis. A theoretical tryptic digestion of 100 randomly selected proteins from the Swiss-Prot databank revealed that small tryptic peptides, with fewer than eight amino acid residues, account for ca 20% of protein coverage.

A second advantage is the possible improvement of the fragmentation in MS/MS mode. The introduction of a fixed charge on the peptide directs fragmentation leading to the generation of predominately a and b type ions with minimal internal rearrangement. They are called respectively  $\text{*a}_n$  and  $\text{*b}_n$ .

## Experimental

### Sample preparation

A lyophilized sample of an ADH digest (Waters, Milford, MA) was dissolved in 100  $\mu\text{L}$  of triethylammonium bicarbonate (Sigma, St Louis, MO)/Acetonitrile (80/20), at a concentration of 10 pmoles/ $\mu\text{L}$ . The peptide solution was made up in Eppendorf tubes (Eppendorf, Germany).

2.5 mg of TMPP-acOSu (Waters, Milford, MA) was dissolved in 60  $\mu\text{L}$  anhydrous acetonitrile, and 0.25  $\mu\text{L}$  of this solution was added to 25  $\mu\text{L}$  of the tryptic digest. The mixture was vortexed and left to stand for 20 minutes. The reaction was subsequently acidified using TFA, and the mixture combined with 5 mg/mL of MALDI matrix solution (alpha-cyano-4-hydroxycinnamic acid). 1  $\mu\text{L}$  of the resulting solution was spotted onto a stainless steel MALDI target plate (Waters, Manchester, UK)




Figure 1. Reaction of TMPP-Ac-OSu with the amine at the peptide N-terminal.

## **Mass Spectrometry**

All data were acquired on a Waters® Micromass® Q-ToF Ultima™ MALDI mass spectrometer in positive ion mode. The instrument was calibrated with a mixture of PEG 200, 600, 1000 and 2000. In MS mode, data were acquired from m/z 800 to 3000. A lockmass, (Glu1)-Fibrinopeptide B, from an adjacent well was used as a near point calibration reference, to enhance the mass measurement accuracy of the data. In the MS/MS mode, the data were acquired from 50 Da to an m/z value of 5% above the parent ion [M+H]<sup>+</sup>.

## **Capillary HPLC system and MALDI target spotting device**

The analytical system consisted of a Waters CapLC® XE System configured with a ten-port switching valve, the stream select module. The HPLC was configured with a Waters Symmetry® C<sub>18</sub> 3.5 µm, 320 µm x 150 mm column. The flow rate was 3 µL/min and peptides were separated using the following solvents: Water + 0.1% TFA and acetonitrile + 0.1% TFA. The initial solvent

composition of 97% water (with 0.1% TFA)/3% acetonitrile was held for the first 3 minutes. A gradient was run with the organic solvent rising up to 60% in 27 minutes, and then to 95% by 30 minutes. The acetonitrile composition then stayed at 95% for 3 minutes to wash the column. Re-equilibration of the column was achieved using the initial conditions for five minutes.

The outlet from the capillary scale HPLC column was attached directly to the MALDI spotting robot, the Waters 2700 MS. The eluent from the HPLC column was spotted onto the MALDI target, with each spot corresponding to 20 seconds of chromatographic elution.

## **Data processing**

Waters Proteinlynx™ Global SERVER 2.0 was used for data processing and database searching. Data were converted to XML format and searched against the Swiss-Prot database v40. MS/MS spectra were deisotoped using MaxEnt 3 (MaxEnt Solution, UK). *De novo* sequencing was performed using Waters MassSeq™ software.




Figure 2. Comparison of underderivatized (top) and TMPP derivatized mass spectra (bottom) obtained from the MALDI MS analysis of an Alcohol Dehydrogenase tryptic digest.

## Results

### Improvements in peptide sequence coverage

Analysis of a native (non-derivatized) ADH tryptic digest yields an average of 10 peptides in a MALDI mass spectrum. This equates to an amino acid sequence coverage of approximately 43% of the protein sequence.

In contrast, analysis of the ADH digest after derivatization with TMPP, resulted in 40 peptides being observed in the mass spectrum. MS/MS experiments were subsequently performed on 35 of these using the Q-ToF Ultima MALDI mass spectrometer.

Of the peptides identified in the modified mass spectrum that were not seen in the unmodified spectrum, 15 had a mass below 850 Da (which is the lower mass limit in MALDI MS due to the

interference of the matrix related peaks). This illustrates the significant number of small peptides, which are present, but not observed in a typical tryptic digest. However, these are observed, following TMPP derivatization of the tryptic peptides. The percentage amino acid sequence coverage, in this case, was increased from 43% to 62% by derivatizing with TMPP-oSu.

The same TMPP-derivatized ADH digest sample has been analyzed by an LC-MALDI approach. In this case the number of peptides analyzed is even greater, with 120 peptides detected, of which 105 were identified using MS/MS on the MALDI Q-ToF. Due to the chromatographic separation of the peptides present, the number of peptides identified was significantly improved, resulting in a rise in the sequence coverage to 84%. The combination of HPLC separation with MALDI MS detection dramatically increased the dynamic range of the experiment.

### Effect of TMPP derivatization upon MS/MS fragmentation patterns

The fragmentation patterns observed in MS/MS for TMPP-derivatized peptides are more predictable than their non-derivatized peptide counterparts. This has previously been studied by several groups, with the most extensive study performed by Sadagopan *et. al.*<sup>1</sup>

In all of the MS/MS spectra obtained from TMPP-modified peptides, fragment ions are observed between 573.1898 Da and the precursor ion mass. The 573.1898 Da ion is the M<sup>+</sup> of the TMPP reagent. This ion at m/z 573.1898 is typically a strong peak in the spectrum, making it a diagnostically useful species, allowing confirmation that the analyzed precursor ion has been derivatized with TMPP. Fragment ions present below m/z 573.1898 are predominantly due to fragments produced from cleavage of the TMPP molecule.

Even if \*a<sub>n</sub> or \*b<sub>n</sub> type ion peaks are not intense compared to precursor ion or to the ion at 573.1898 Da, it is possible to detect and identify them. As internal rearrangement is not favored from these derivatized species, noise in the MS/MS spectrum obtained from TMPP derivatized peptide molecules is very low.

After analyzing a significant number of TMPP-derivatized MS/MS spectra from the ADH tryptic digest, it can be concluded that:

- Almost exclusively N-terminal \*a<sub>n</sub> and \*b<sub>n</sub> type ions were identified.
- For 86% of the fragments the \*a<sub>n</sub> ions were more intense than the \*b<sub>n</sub> ions.
- These findings are in close agreement with those of Sadagopan *et. al.*<sup>1</sup> The two mechanisms are not deductive but separate. An ion formation mechanism for \*a<sub>n</sub> ion has been suggested.<sup>1</sup> (See Figure 3)




Figure 3. Mechanism of fragmentation for the \*a<sub>n</sub> ion formation.




Figure 4. Mechanism of fragmentation for the C<sup>+</sup>-G ion formation.

- 92% of the Aspartic Acid C-term fragments gave only b ion (a ions were not observed).
- 97% of the Proline C-term fragments gave neither \*a<sub>n</sub> nor \*b<sub>n</sub> ions. The hydrogen attached to the amide is believed to be fundamental to the fragmentation process.<sup>1</sup> However, there is no hydrogen of that sort in the case of the Proline residue, which explains why the Proline C-terminal fragments are not seen.

- 13% of the fragments did not give any ions. However 5% are due to a Proline C-terminal, which as stated above is problematical.
- The quality of the fragmentation does not seem to be C-terminal dependant (except in the case of the Proline C-terminal peptide) as has been suggested by A. Pashkova *et. al.*<sup>2</sup>
- Of the 105 derivatized peptides, not all were tryptic peptides and 19 different amino acids were present at the C-terminal included Arginine and Lysine. Apart from the presence of a Proline at the C-terminus, the rest of the commonly occurring amino acids, when present at the C-terminus resulted in an MS/MS spectrum that gave good fragmentation.
- In general it may be observed that larger peptides don't fragment as well as small peptides.
- As described by Sadagopan *et. al.*<sup>1</sup>, a fragment which represents the neutral loss of the C-term amino acid is observed in almost all the spectra. In the data presented here, 97% of the spectra had a peak which represents a neutral loss from the C-terminal.
- Sadagopan *et. al.*<sup>1</sup> have proposed previously that this neutral loss can be structurally informative and proposed a fragmentation mechanism as shown in Figure 4.

# Application Note

Waters

The following spectra are illustrations of the differences in fragmentation between underderivatized (bottom spectra) and derivatized (top spectra) ADH peptides on the Q-ToF Ultima MALDI.

Complete sequence was obtained for both fragmentations. However the derivatized peptide gave less re-arrangement fragmentation peaks, which make the interpretation easier.




Figure 5a. Peptide HH<sup>+</sup>=968.48 Da (EALDDFFAR).




Figure 5b. Peptide MH<sup>+</sup>=1251.67 Da (SISIVGSYVGNGR).




Figure 5c. Peptide  $\text{MH}^+=2019.07$  Da (LPLVGGHEGAGVVVGGMGENVK).

Sequence from  $y_4$  to  $y_9$  was found for the underderivatized peptide, whereas almost a complete sequence was obtained with the derivatized peptide fragmentation.

The MS/MS spectrum of the underderivatized peptide is much more difficult to interpret because of the larger number of different fragment ions. The derivatized peptide fragmentation gave almost exclusively  $*\text{a}_n$  and  $*\text{b}_n$  fragment peaks. Also, more continuous sequence information was obtained.

### Conclusion

- TMPP modification is a quick and easy reaction.
- Analysis of TMPP derivatized tryptic peptides in the MS mode can improve the amino acid sequence coverage of the proteins identified in a PMF experiment. Without chromatography, 62% amino acid coverage of the protein was achieved. Combining with LC-MALDI separation identified a further 22% of the ADH sequence,

which brings the combined coverage to 84%. Prior to derivatization the sequence coverage observed for ADH was 43%.

- In the MALDI MS/MS mode, the fragmentation is improved with the derivatized peptide. This is not always the case for larger peptides.
- The predictability of the fragmentation allows for easier *de novo* sequencing. The fragmentation parameters can be implemented in a software algorithm for automated *de novo* sequencing.

### Reference

1. Sadagopan, N; Throck Watson, J. *J Am Soc Mass Spectrom* 2001, 12, 399–409.
2. Pashkova, A, Barnett Institute and Department of Chemistry, Northeastern University, Boston, MA, *Poster at ASMS 2003: Derivatization of peptides for Analysis by High-Throughput LC-MALDI-MS/MS*.

## Sales Offices:

AUSTRIA 43 1 877 18 07	KOREA 82 2 820 2700
AUSTRALIA 61 2 9933 1777	MEXICO 52 55 5524 7636
BELGIUM AND LUXEMBOURG 32 2 726 1000	THE NETHERLANDS 31 76 508 7200
BRAZIL 55 11 5543 7788	NORWAY 47 6 384 6050
CANADA 800 252 4752 X2205	PEOPLE'S REPUBLIC OF CHINA 86 10 8451 8918
CZECH REPUBLIC 420 2 617 11384	POLAND 48 22 833 4400
DENMARK 45 46 59 8080	PUERTO RICO 787 747 8445
FINLAND 358 9 506 4140	RUSSIA/CIS 7 095 931 9193
FRANCE 33 1 3048 7200	SINGAPORE 65 6278 7997
GERMANY 49 6196 400600	SPAIN 34 93 600 9300
HONG KONG 852 29 64 1800	SWEDEN 46 8 555 11 500
HUNGARY 36 1 350 5086	SWITZERLAND 41 62 889 2030
INDIA 91 80 2837 1900	TAIWAN 886 2 2543 1898
IRELAND 353 1 448 1500	UK 44 208 238 6100
ITALY 39 02 27 4211	US 800 252 4752
JAPAN 81 3 3471 7191	

# Waters

WATERS CORPORATION  
34 Maple St.  
Milford, MA 01757 U.S.A.  
T: 508 478 2000  
F: 508 872 1990  
[www.waters.com](http://www.waters.com)

For Complete Confidence

Waters, Micromass, Q-ToF Ultima, CapLC, Symmetry, ProteinLynx and MassSeq are trademarks of Waters Corporation.

All other trademarks are property of their respective owners.

©2004 Waters Corporation Produced in the U.S.A. September 2004 720000958EN LL-PDF

